ASMB
Assembly Biosciences, Inc.
Biotechnology
Market Cap$492M
5Y Perf.-86.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ASMB vs REPL vs IOVA vs ALNY
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$266M
5Y Perf.-82.2%
IOVA
Iovance Biotherapeutics, Inc.
Biotechnology
Market Cap$1.27B
5Y Perf.-88.9%
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$39.48B
5Y Perf.+118.8%
ASMB vs REPL vs IOVA vs ALNY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASMB | REPL | IOVA | ALNY |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $492M | $266M | $1.27B | $39.48B |
| Revenue (TTM) | $63M | $0.00 | $286M | $4.29B |
| Net Income (TTM) | $-6M | $-315M | $-354M | $577M |
| Gross Margin | 74.3% | — | 114.5% | 80.9% |
| Operating Margin | -21.5% | — | -127.2% | 17.5% |
| Forward P/E | — | — | — | 44.2x |
| Total Debt | $3M | $76M | $48M | $1.28B |
| Cash & Equiv. | $58M | $111M | $163M | $1.66B |
ASMB vs REPL vs IOVA vs ALNY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASMB
REPL
IOVA
ALNY
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Assembly Bioscience… (ASMB) | 100 | 13.2 | -86.8% |
| Replimune Group, In… (REPL) | 100 | 17.8 | -82.2% |
| Iovance Biotherapeu… (IOVA) | 100 | 11.1 | -88.9% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 218.8 | +118.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASMB vs REPL vs IOVA vs ALNY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALNY leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Assembly Biosciences, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ASMB
Assembly Biosciences, Inc.
The Growth Play
ASMB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 153.5%, EPS growth 91.8%
- 153.5% revenue growth vs REPL's -39.7%
- +149.2% vs REPL's -53.4%
Best for: growth exposure
REPL
Replimune Group, Inc.
The Defensive Pick
REPL is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.83, Low D/E 18.3%, current ratio 7.95x
- Beta 0.83, current ratio 7.95x
Best for: sleep-well-at-night and defensive
IOVA
Iovance Biotherapeutics, Inc.
The Growth Angle
IOVA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
ALNY
Alnylam Pharmaceuticals, Inc.
The Income Pick
ALNY carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.71
- 411.9% 10Y total return vs IOVA's -34.3%
- 13.5% margin vs IOVA's -123.9%
- Beta 0.71 vs IOVA's 2.01
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ASMB | 153.5% revenue growth vs REPL's -39.7% |
| Quality / Margins | ALNY | 13.5% margin vs IOVA's -123.9% |
| Stability / Safety | ALNY | Beta 0.71 vs IOVA's 2.01 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ASMB | +149.2% vs REPL's -53.4% |
| Efficiency (ROA) | ALNY | 11.8% ROA vs REPL's -94.4%, ROIC 33.4% vs -51.9% |
ASMB vs REPL vs IOVA vs ALNY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2025
ASMB vs REPL vs IOVA vs ALNY — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALNYLAGGINGIOVA
Who Leads Where
ALNY leads in 2 of 6 categories
ASMB leads 1 • REPL leads 0 • IOVA leads 0 • 2 tied
Explore the data ↓IOVAIovance Biotherapeuti…
0leads
REPLReplimune Group, Inc.
0leads
ASMBAssembly Biosciences,…
1leads
ALNYAlnylam Pharmaceutica…
2leads
6 Total Categories
CATEGORYLEADERvs ASMBvs REPLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALNY5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALNY7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ASMB3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALNY leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALNY and REPL operate at a comparable scale, with $4.3B and $0 in trailing revenue. ALNY is the more profitable business, keeping 13.5% of every revenue dollar as net income compared to IOVA's -123.9%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ASMBAssembly Bioscien… | REPLReplimune Group, … | IOVAIovance Biotherap… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $63M | $0 | $286M | $4.3B |
| EBITDAEarnings before interest/tax | -$13M | -$323M | -$330M | $677M |
| Net IncomeAfter-tax profit | -$6M | -$315M | -$354M | $577M |
| Free Cash FlowCash after capex | -$40M | -$283M | -$305M | $641M |
| Gross MarginGross profit ÷ Revenue | +74.3% | — | +114.5% | +80.9% |
| Operating MarginEBIT ÷ Revenue | -21.5% | — | -127.2% | +17.5% |
| Net MarginNet income ÷ Revenue | -10.2% | — | -123.9% | +13.5% |
| FCF MarginFCF ÷ Revenue | -63.3% | — | -106.8% | +15.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — | +44.8% | +96.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +53.8% | +2.5% | +47.2% | +4.4% |
ALNY leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — ASMB and REPL and IOVA each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ASMBAssembly Bioscien… | REPLReplimune Group, … | IOVAIovance Biotherap… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| Market CapShares × price | $492M | $266M | $1.3B | $39.5B |
| Enterprise ValueMkt cap + debt − cash | $436M | $231M | $1.2B | $39.1B |
| Trailing P/EPrice ÷ TTM EPS | -56.24x | -1.09x | -3.26x | 127.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 44.18x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 70.17x |
| Price / SalesMarket cap ÷ Revenue | 6.80x | — | 4.82x | 10.63x |
| Price / BookPrice ÷ Book value/share | 1.68x | 0.65x | 1.82x | 50.50x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 84.84x |
Evenly matched — ASMB and REPL and IOVA each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ALNY leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALNY delivers a 98.3% return on equity — every $100 of shareholder capital generates $98 in annual profit, vs $-150 for REPL. ASMB carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 1.62x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs REPL's 2/9, reflecting solid financial health.
| Metric | ASMBAssembly Bioscien… | REPLReplimune Group, … | IOVAIovance Biotherap… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -4.2% | -149.5% | -50.2% | +98.3% |
| ROA (TTM)Return on assets | -3.1% | -94.4% | -38.8% | +11.8% |
| ROICReturn on invested capital | -12.2% | -51.9% | -48.9% | +33.4% |
| ROCEReturn on capital employed | -8.7% | -55.9% | -51.6% | +15.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.01x | 0.18x | 0.07x | 1.62x |
| Net DebtTotal debt minus cash | -$56M | -$35M | -$115M | -$379M |
| Cash & Equiv.Liquid assets | $58M | $111M | $163M | $1.7B |
| Total DebtShort + long-term debt | $3M | $76M | $48M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -48.62x | — | 2.02x |
ALNY leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ASMB leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNY five years ago would be worth $22,537 today (with dividends reinvested), compared to $932 for REPL. Over the past 12 months, ASMB leads with a +149.2% total return vs REPL's -53.4%. The 3-year compound annual growth rate (CAGR) favors ASMB at 35.3% vs REPL's -43.0% — a key indicator of consistent wealth creation.
| Metric | ASMBAssembly Bioscien… | REPLReplimune Group, … | IOVAIovance Biotherap… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -8.4% | -62.5% | +40.9% | -26.1% |
| 1-Year ReturnPast 12 months | +149.2% | -53.4% | +13.4% | +7.0% |
| 3-Year ReturnCumulative with dividends | +147.8% | -81.5% | -49.9% | +40.9% |
| 5-Year ReturnCumulative with dividends | -36.5% | -90.7% | -87.6% | +125.4% |
| 10-Year ReturnCumulative with dividends | -47.8% | -78.0% | -34.3% | +411.9% |
| CAGR (3Y)Annualised 3-year return | +35.3% | -43.0% | -20.6% | +12.1% |
ASMB leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ASMB and ALNY each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALNY is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than IOVA's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASMB currently trades 77.9% from its 52-week high vs REPL's 25.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASMBAssembly Bioscien… | REPLReplimune Group, … | IOVAIovance Biotherap… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.67x | 0.83x | 2.01x | 0.71x |
| 52-Week HighHighest price in past year | $39.71 | $13.24 | $5.63 | $495.55 |
| 52-Week LowLowest price in past year | $11.64 | $1.50 | $1.64 | $245.96 |
| % of 52W HighCurrent price vs 52-week peak | +77.9% | +25.2% | +63.1% | +59.7% |
| RSI (14)Momentum oscillator 0–100 | 64.5 | 46.3 | 63.1 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 103K | 5.6M | 16.2M | 1.1M |
Evenly matched — ASMB and ALNY each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ASMB as "Buy", REPL as "Buy", IOVA as "Buy", ALNY as "Buy". Consensus price targets imply 274.3% upside for REPL (target: $13) vs -43.7% for IOVA (target: $2).
| Metric | ASMBAssembly Bioscien… | REPLReplimune Group, … | IOVAIovance Biotherap… | ALNYAlnylam Pharmaceu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $12.50 | $2.00 | $445.67 |
| # AnalystsCovering analysts | 11 | 15 | 20 | 52 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALNY leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ASMB leads in 1 (Total Returns). 2 tied.
Best OverallAlnylam Pharmaceuticals, In… (ALNY)Leads 2 of 6 categories
Loading custom metrics...
ASMB vs REPL vs IOVA vs ALNY: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ASMB or REPL or IOVA or ALNY a better buy right now?
For growth investors, Assembly Biosciences, Inc.
(ASMB) is the stronger pick with 153. 5% revenue growth year-over-year, versus 60. 6% for Iovance Biotherapeutics, Inc. (IOVA). Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 127. 0x trailing P/E (44. 2x forward), making it the more compelling value choice. Analysts rate Assembly Biosciences, Inc. (ASMB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASMB or REPL or IOVA or ALNY?
Over the past 5 years, Alnylam Pharmaceuticals, Inc.
(ALNY) delivered a total return of +125. 4%, compared to -90. 7% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus REPL's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASMB or REPL or IOVA or ALNY?
By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.
(ALNY) is the lower-risk stock at 0. 71β versus Iovance Biotherapeutics, Inc. 's 2. 01β — meaning IOVA is approximately 184% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Assembly Biosciences, Inc. (ASMB) carries a lower debt/equity ratio of 1% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ASMB or REPL or IOVA or ALNY?
By revenue growth (latest reported year), Assembly Biosciences, Inc.
(ASMB) is pulling ahead at 153. 5% versus 60. 6% for Iovance Biotherapeutics, Inc. (IOVA). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to 5. 2% for Replimune Group, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ASMB or REPL or IOVA or ALNY?
Alnylam Pharmaceuticals, Inc.
(ALNY) is the more profitable company, earning 8. 4% net margin versus -148. 4% for Iovance Biotherapeutics, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -153. 1% for IOVA. At the gross margin level — before operating expenses — ASMB leads at 99. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ASMB or REPL or IOVA or ALNY more undervalued right now?
Analyst consensus price targets imply the most upside for REPL: 274.
3% to $12. 50.
07Which pays a better dividend — ASMB or REPL or IOVA or ALNY?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ASMB or REPL or IOVA or ALNY better for a retirement portfolio?
For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +411. 9%, IOVA: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ASMB and REPL and IOVA and ALNY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ASMB is a small-cap high-growth stock; REPL is a small-cap quality compounder stock; IOVA is a small-cap high-growth stock; ALNY is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.